Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for PT Bundamedik Tbk's Net Margin % or its related term are showing as below:
ISX:BMHS'
s Net Margin % Range Over the Past 10 Years
Min: -0.07 Med: 1.42 Max: 11.34
Current: -0.07
ISX:BMHS's Net Margin % is ranked worse than 66.17% of 665
companies
in the Healthcare Providers & Services industry
Industry Median: 3
vs ISX:BMHS: -0.07
PT Bundamedik Tbk (ISX:BMHS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
PT Bundamedik Tbk Net Margin % Related Terms
PT Bundamedik Tbk Net Margin % Historical Data
* Premium members only.
The historical data trend for PT Bundamedik Tbk's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:BMHS vs HCA, THC, DVA: Net Margin % Comparison
For the Medical Care Facilities subindustry, PT Bundamedik Tbk's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Bundamedik Tbk Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Bundamedik Tbk's Net Margin % distribution charts can be found below:
* The bar in red indicates where PT Bundamedik Tbk's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Bundamedik Tbk (ISX:BMHS) has a Net Margin % of -2.44% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on PT Bundamedik Tbk and its competitors. According to the industry distribution chart, PT Bundamedik Tbk ranks #440 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 66.2%.
Is PT Bundamedik Tbk's Net Margin % too high?
PT Bundamedik Tbk's current Net Margin % is -2.44%. Based on the distribution chart, PT Bundamedik Tbk ranks #440 out of 665 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, PT Bundamedik Tbk has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Bundamedik Tbk's Net Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Bundamedik Tbk ranks #440 out of 665 companies for Net Margin %. This places PT Bundamedik Tbk in the lower half of its industry. The industry median Net Margin % is 3.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 3.00, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on PT Bundamedik Tbk and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Bundamedik Tbk's current Net Margin % is -2.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Bundamedik Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Bundamedik Tbk (ISX:BMHS) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp261.49, compared to a current price of Rp189.00 — trading 27.7% below its estimated fair value. The current Net Margin % is -2.44%. PT Bundamedik Tbk's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For PT Bundamedik Tbk (ISX:BMHS), the current Net Margin % is -2.44% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Bundamedik Tbk (ISX:BMHS) Overvalued in 2026?
Based on GuruFocus' analysis, PT Bundamedik Tbk stock appears to be undervalued.
The current stock price of Rp189.00 is trading 27.7% below its estimated GF Value™ of Rp261.49.
GuruFocus considers PT Bundamedik Tbk to be Modestly Undervalued.
Key valuation signals for ISX:BMHS:
Net Margin %: -2.44%
GF Value™: Rp261.49 vs. price of Rp189.00 (27.7% below fair value)
No single metric tells the full story. See the ISX:BMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Bundamedik Tbk is a healthcare service provider. The Company carries out its main business activities through private hospital activities. It offers maternal and child health services, outpatient services, inpatient services, emergency services, service excellence centers, IVF services, and Clinical laboratory services.
63GF Score
Get the complete analysis for ISX:BMHS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:BMHS has been successfully added to your 
